Biogen and partner Eisai had been hoping for good news from the review of Aduhelm (aducanumab) by the Centre for Medicare and Medicaid Services (CMS), but the draft decision means broad coverage of the drug will have to wait for the outcome of ongoing studies before it can hope for broader coverage.
While the decision only applies to reimbursement for patients receiving the drug via the federal healthcare schemes, private insurers may opt to follow the same guidelines, stopping the drug’s rollout in its tracks.
